1
|
Pisano S, Pierini I, Gu J, Gazze A, Francis LW, Gonzalez D, Conlan RS, Corradetti B. Immune (Cell) Derived Exosome Mimetics (IDEM) as a Treatment for Ovarian Cancer. Front Cell Dev Biol 2020; 8:553576. [PMID: 33042993 PMCID: PMC7528637 DOI: 10.3389/fcell.2020.553576] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Accepted: 08/20/2020] [Indexed: 12/12/2022] Open
Abstract
Exosomes are physiologically secreted nanoparticles recently established as natural delivery systems involved in cell-to-cell communication and content exchange. Due to their inherent targeting potential, exosomes are currently being harnessed for the development of anti-cancer therapeutics. Clinical trials evaluating their effectiveness are demonstrating safety and promising outcomes. However, challenging large-scale production, isolation, modification and purification of exosomes are current limitations for the use of naturally occurring exosomes in the clinic. Exosome mimetics hold the promise to improve the delivery of bioactive molecules with therapeutic efficacy, while achieving scalability and increasing bioavailability. In this study, we propose the development of Immune Derived Exosome Mimetics (IDEM) as a scalable approach to target and defeat ovarian cancer cells. IDEM were fabricated from monocytic cells by combining sequential filtration steps through filter membranes with different porosity and size exclusion chromatography columns. The physiochemical and molecular characteristics of IDEM were compared to those of natural exosomes (EXO). Nanoparticle Tracking Analysis confirmed a 2.48-fold increase in the IDEM production yields compared to EXO, with similar exosomal markers profiles (CD81, CD63) as demonstrated by flow cytometry and ELISA. To exploit the prospective of IDEM to deliver chemotherapeutics, doxorubicin (DOXO) was used as a model drug. IDEM showed higher encapsulation efficiency and drug release over time compared to EXO. The uptake of both formulations by SKOV-3 ovarian cancer cells was assessed by confocal microscopy and flow cytometry, showing an incremental drug uptake over time. The analysis of the cytotoxic and apoptotic effect of DOXO-loaded nanoparticles both in 2D and 3D culture systems proved IDEM as a more efficient system as compared to free DOXO, unraveling the advantage of IDEM in reducing side-effects while increasing cytotoxicity of targeted cells, by delivering smaller amount of the chemotherapeutic agent. The high yields of IDEM obtained compared to natural exosomes together with the time-effectiveness and reproducibility of their production method make this approach potentially exploitable for clinical applications. Most importantly, the appreciable cytotoxic effect observed on ovarian cancer in vitro systems sets the ground for the development of compelling nanotherapeutic candidates for the treatment of this malady and will be further evaluated.
Collapse
Affiliation(s)
- Simone Pisano
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States.,Centre for NanoHealth, Swansea University Medical School, Swansea, United Kingdom
| | - Irene Pierini
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States
| | - Jianhua Gu
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States
| | - Andrea Gazze
- Centre for NanoHealth, Swansea University Medical School, Swansea, United Kingdom
| | - Lewis Webb Francis
- Centre for NanoHealth, Swansea University Medical School, Swansea, United Kingdom
| | - Deyarina Gonzalez
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States
| | - Robert Steven Conlan
- Centre for NanoHealth, Swansea University Medical School, Swansea, United Kingdom
| | - Bruna Corradetti
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States.,Centre for NanoHealth, Swansea University Medical School, Swansea, United Kingdom
| |
Collapse
|
2
|
Clabault H, Flipo D, Guibourdenche J, Fournier T, Sanderson JT, Vaillancourt C. Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization. Toxicol Appl Pharmacol 2018; 349:8-20. [PMID: 29679653 DOI: 10.1016/j.taap.2018.04.018] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 03/27/2018] [Accepted: 04/14/2018] [Indexed: 12/19/2022]
Abstract
Selective serotonin-reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants during pregnancy. The human placenta is a highly specialized organ supporting normal growth and development of the fetus. Therefore, this study aims to analyze the effects of SSRIs on villous cytotrophoblasts cells, using BeWo cells and human placental trophoblast cells in primary culture. The SSRIs fluoxetine and its metabolite norfluoxetine, sertraline and venlafaxine did not affect BeWo cell proliferation and viability, nor the percentage of M30-positive (apoptotic) primary trophoblast cells. None of the SSRIs affected basal or forskolin-stimulated BeWo cell fusion, whereas sertraline and venlafaxine increased the fusion of primary villous trophoblasts. Sertraline and venlafaxine also modified human chorionic gonadotropin beta (β-hCG) secretion by BeWo cells, whereas none of the SSRIs affected β-hCG secretion in primary trophoblasts. Norfluoxetine increased CGB (chorionic gonadotropin beta) and GJA1 (gap junction protein alpha 1) levels of gene expression (biomarkers of syncytialization) in BeWo cells, whereas in primary trophoblasts none of the SSRIs tested affected the expression of these genes. This study shows that SSRIs affect villous trophoblast syncytialization in a structure- and concentration-dependent manner and suggests that certain SSRIs may compromise placental health. In addition, it highlights the importance of using primary trophoblast cells instead of "trophoblast -like" cell lines to assess the effects of medications on human villous trophoblast function.
Collapse
Affiliation(s)
- Hélène Clabault
- INRS-Institut Armand-Frappier, 531 blvd des Prairies, Laval, QC, H7V 1B7, Canada; BioMed Research Centre, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada; Center for Interdisciplinary Research on Well-Being, Health, Society and Environment, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada.
| | - Denis Flipo
- BioMed Research Centre, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada; Département des Sciences Biologiques, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada.
| | - Jean Guibourdenche
- INSERM, UMR-S1139, Faculté de Pharmacie de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris F-75006, France; Service d'hormonologie Centre Hospitalier, Universitaire Cochin Broca Hôtel Dieu, Assistance Publique-Hôpital de Paris, Paris F-75014, France.
| | - Thierry Fournier
- INSERM, UMR-S1139, Faculté de Pharmacie de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris F-75006, France; Fondation PremUp, Paris F-75006, France.
| | - J Thomas Sanderson
- INRS-Institut Armand-Frappier, 531 blvd des Prairies, Laval, QC, H7V 1B7, Canada.
| | - Cathy Vaillancourt
- INRS-Institut Armand-Frappier, 531 blvd des Prairies, Laval, QC, H7V 1B7, Canada; BioMed Research Centre, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada; Center for Interdisciplinary Research on Well-Being, Health, Society and Environment, Université du Québec à Montréal, Montréal, QC H3C 3P8, Canada.
| |
Collapse
|